According to a recent LinkedIn post from Cleerly, the company is emphasizing the clinical importance of differentiating between hard, calcified plaque and soft, non‑calcified plaque in coronary arteries. The post suggests that soft plaque poses higher risk, is more prone to rupture, and may be under‑detected by traditional diagnostic methods.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights Cleerly’s use of advanced plaque analysis on non‑invasive CCTA imaging, which the company says can color‑code and quantify multiple plaque types. The message positions this capability as addressing limitations of conventional tests, implying potential value in more precise risk stratification and earlier intervention in cardiac care.
The post also notes the existence of a new Category I CPT code and broader insurance coverage for the technology, indicating that Cleerly’s offering is now reimbursable for a majority of insured lives in the U.S. If accurate, this reimbursement status could materially support adoption by healthcare providers and improve revenue visibility by reducing payer‑related barriers.
For investors, the combination of differentiated imaging analytics and expanding reimbursement may signal a more favorable commercialization environment and a maturing business model. Wider coverage could drive higher scan volumes and recurring software usage, potentially strengthening Cleerly’s competitive position in AI‑enabled cardiology diagnostics and supporting longer‑term growth prospects in the cardiovascular imaging market.